Journal
CANCERS
Volume 10, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/cancers10040103
Keywords
pancreatic cancer; pancreatic adenocarcinoma; virotherapy; oncolytic; non-viral vector; RNA interference; siRNA
Categories
Funding
- NIH/NIDDK [T32DK108733]
- [R01CA196215]
- [R01CA168448]
Ask authors/readers for more resources
Mortality from pancreatic ductal adenocarcinoma (PDAC) has remained essentially unchanged for decades and its relative contribution to overall cancer death is projected to only increase in the coming years. Current treatment for PDAC includes aggressive chemotherapy and surgical resection in a limited number of patients, with median survival of optimal treatment rather dismal. Recent advances in gene therapies offer novel opportunities for treatment, even in those with locally advanced disease. In this review, we summarize emerging techniques to the design and administration of virotherapy, synthetic vectors, and gene-editing technology. Despite these promising advances, shortcomings continue to exist and here will also be highlighted those approaches to overcoming obstacles in current laboratory and clinical research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available